犬血清中MMP2和MMP9与肿瘤疾病的相关性研究

江鲜雨; 裴世敏

doi:10.13881/j.cnki.hljxmsy.2022.12.0145

犬血清中MMP2和MMP9与肿瘤疾病的相关性研究

海南大学动物科技学院

基金项目:

新瑞鹏宠物医疗集团有限公司、深圳市瑞鹏公益基金会高校青年教师(小动物临床)科研基金项目(RPJJ2020015)

详细信息

作者简介:
江鲜雨(1998—),女,硕士研究生,研究方向为小动物肿瘤学,610393766@qq.com

通讯作者:
裴世敏(1987—),女,讲师,博士,硕士生导师,研究方向为小动物肿瘤学,peishimin@hainanu.edu.cn

中图分类号: S858.292
计量
- 文章访问数: 1
- HTML全文浏览量: 0
- PDF下载量: 0
出版历程
- 收稿日期: 2022-12-18
- 刊出日期: 2023-06-19

Study on the correlation between serum MMP2/MMP9 and tumor diseases in canine

College of Animal Science and Technology, Hainan University

摘要

摘要: 为了在兽医临床上找到用于犬肿瘤疾病的血清生物标志物，试验采集113份犬血清样本，分别采用酶联免疫吸附测定(ELISA)法和明胶酶谱分析方法检测血清样本中MMP2与MMP9蛋白的质量浓度和活性，并对犬血清中MMP2和MMP9蛋白的质量浓度与活性进行了相关性分析。结果表明：肿瘤犬血清中MMP2和MMP9蛋白的质量浓度(中位数分别为126.76μg/mL和230.31μg/mL)均显著高于非肿瘤犬血清中MMP2和MMP9的蛋白质量浓度(中位数分别为58.90μg/mL和55.14μg/mL,P<0.05);≥7岁的非肿瘤犬血清中MMP2蛋白质量浓度极显著高于<7岁的非肿瘤犬(P<0.01),MMP9蛋白质量浓度略高于<7岁的非肿瘤犬(P>0.05);≥7岁的肿瘤犬血清中MMP2和MMP9蛋白质量浓度均略高于<7岁的肿瘤犬(P>0.05);<7岁和≥7岁的肿瘤犬血清中MMP2蛋白质量浓度均显著高于同年龄段的非肿瘤犬(P<0.05);不同肿瘤类型的肿瘤犬血清中MMP2蛋白质量浓度差异不显著(P>0.05);乳腺肿瘤、肉瘤和其他肿瘤中MMP9蛋白质量浓度极显著高于肥大细胞瘤(P<0.01),显著高于淋巴瘤(P<0.05);肿瘤犬血清中MMP2和MMP9蛋白的活性均略高于非肿瘤犬(P>0.05);在非肿瘤犬血清样本中，MMP2和MMP9蛋白的质量浓度与活性均无相关性；在肿瘤犬血清样本中，MMP2和MMP9蛋白的质量浓度与活性均呈弱相关性。说明肿瘤犬血清中MMP2和MMP9蛋白的质量浓度和活性均在一定程度上高于非肿瘤犬，具有作为肿瘤早期诊断和预后标志物的潜能。
- 肿瘤 /
- 标志物 /
- 血清 /
- 基质金属蛋白酶2 /
- 基质金属蛋白酶9
Abstract: In order to identify serum biomarkers for canine tumor diseases in veterinary clinic, enzyme-linked immunosorbent assay（ELISA） and gelatin enzyme assay were used to detect the protein mass concentration and activity of MMP2 and MMP9 in serum samples from 113 dog cases, and the correlation between the protein mass concentration and activity of MMP2 and MMP9 in dog serum was analyzed. The results showed that the protein concentrations of MMP2 and MMP9 in serum of tumor dogs（median 126.76 μg/mL and 230.31 μg/mL, respectively） were significantly higher than those in serum of non-tumor dogs（median 58.90 μg/mL and 55.14 μg/mL, P＜0.05）. The serum MMP2 protein mass concentration of ≥7 years old non-tumor dogs was significantly higher than that of ＜7 years old non-tumor dogs（P＜0.01）, and the serum MMP9 protein mass concentration of ≥7 years old non-tumor dogs was slightly higher than that of ＜7 years old non-tumor dogs（P＞0.05）, and the serum MMP2 and MMP9 protein mass concentrations of ≥7 years old tumor dogs were slightly higher than that of ＜7 years old non-tumor dogs（P＞0.05）. The serum MMP2 protein mass concentration of ＜7 years old and ≥7 years old tumor dogs was significantly higher than that of same age group of non-tumor dogs（P＜0.05）.There were no significant differences in MMP2 protein mass concentrations among different tumor types（P＞0.05）. The protein mass concentrations of MMP9 of breast tumors, sarcomas and other masses were extremely significantly higher than those of mastocytoma（P＜0.01）, and significantly higher than those of lymphoma（P＜0.05）.The protein activities of MMP2 and MMP9 in serum of tumor dogs were slightly higher than those of non-tumor dogs（P＞0.05）. In the serum samples of non-tumor dogs, the protein mass concentrations of MMP2 and MMP9 were not correlated with the protein activity. The protein mass concentrations of MMP2 and MMP9 were weakly correlated with the protein activity in the serum samples of tumor dogs. These results indicated that the protein mass concentration and activity of MMP2 and MMP9 in serum of tumor dogs were improved to a certain extent compared with non-tumor dogs, which had the potential to be used as markers for early diagnosis and prognosis of tumor.
- tumor /
- biomarker /
- serum /
- MMP2 /
- MMP9

HTML全文

参考文献(39)

[1]	GOLDSCHMIDT M,PEÑA L,RASOTTO R,et al.Classification and grading of canine mammary tumors[J].Vet Pathol,2011,48(1):117-131.
[2]	VALDIVIA G,ALONSO-DIEZÁ,ALONSO-MIGUEL D,et al.Epitheliosis is a histopathological finding associated with malignancy and poor prognosis in dogs with mammary tumors[J].Vet Pathol,2022,59(5):747-758.
[3]	CANADAS A,FRANA M,PEREIRA C,et al.Canine mammary tumors:comparison of classification and grading methods in a survival study[J].Vet Pathol,2019,56(2):208-219.
[4]	HOSSEINI E,PEDRAM B,BAHRAMI A M,et al.Cutaneous mast cell tumor (mastocytoma):cytohistopathological and haematological investigations[J].Diagn Pathol,2014,9:9.
[5]	KINSELLA A,GREEN B,LEPTS G,et al.The role of the cellcell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis[J].Br J Cancer,1993,67:904-909.
[6]	PRAKASH S S.Cavitation of tumoral basement membrane as onset of cancer invasion and metastasis:physics of oncogenic homeorhesis via nonlinear mechano-metabolomics[J].Converg Sci Phys Oncol,2016,2(1):015001.
[7]	VU H T,HOANG T X,KIM J Y.All-trans retinoic acid enhances matrix metalloproteinase 2 expression and secretion in human myeloid leukemia THP-1 cells[J].Bio Med Res Int,2018,2018:1-10.
[8]	GIALELI C,KARAMANOS N K,SKANDALIS S S,et al.Extracellular matrix structure[J].Adv Drug Deliv Rev,2016,97:4-27.
[9]	FANJUL-FERNÁNDEZ M,FOLGUERAS A R,CABRERA S,et al.Matrix metalloproteinases:evolution,gene regulation and functional analysis in mouse models[J].Biochim Biophys Acta,2010,1803(1):3-19.
[10]	GIANNELLI G,ANTONACI S.Gelatinases and their inhibitors in tumor metastasis:from biological research to medical applications[J].Histol Histopathol,2002,17(1):339-345.
[11]	BJÖRKLUND M,KOIVUNEN E.Gelatinase-mediated migration and invasion of cancer cells[J].Biochim Biophys Acta,2005,1755(1):37-69.
[12]	WINER A,ADAMS S,MIGNATTI P.Matrix metalloproteinase inhibitors in cancer therapy:turning past failures into future successes[J].Mol Cancer Ther,2018,17(6):1147-1155.
[13]	GONZALEZ-AVILA G,SOMMER B,MENDOZA-POSADA D A,et al.Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer[J].Crit Rev Oncol Hematol,2019,137:57-83.
[14]	QUINTERO-FABIÁN S,ARREOLA R,BECERRIL-VILLANUEVA E,et al.Role of matrix metalloproteinases in angiogenesis and cancer[J].Front Oncol,2019,9:1370.
[15]	FIELDS G B.Mechanisms of action of novel drugs targeting angiogenesis promoting matrix metalloproteinases[J].Front Immunol,2019,10:1278.
[16]	SCANNEVIN R H,ALEXANDER R,HAARLANDER T M,et al.Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation[J].J Biol Chem,2017,292(43):17963-17974.
[17]	DAS S,AMIN S A,JHA T.Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies[J].Eur J Med Chem,2021,223:113623.
[18]	BROWN G T,MURRAY G I.Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis[J].J Pathol,2015,237(3):273-281.
[19]	GKOUVERIS I,NIKITAKIS N G,ASEERVATHAM J,et al.Matrix metalloproteinases in head and neck cancer:current perspectives[J].Metalloproteinases Med,2017,4:47-61.
[20]	PAN S,HU Y,HU M,et al.Platelet-derived PDGF promotes the invasion and metastasis of cholangiocarcinoma by upregulating MMP2/MMP9 expression and inducing EMT via the p38/MAPKsignalling pathway[J].Am J Transl Res,2020,12 (7):3577-3595.
[21]	HOLLBORN M,STATHOPOULOS C,STEFFEN A,et al.Positive feedback regulation between MMP-9 and VEGF in human RPEcells[J].Invest Ophthalmol Vis Sci,2007,48(9):4360-4367.
[22]	MUGHEES M,SENGUPTA A,KHOWAL S,et al.Mechanism of tumour microenvironment in the progression and development of oral cancer[J].Mol Biol Rep,2021,48(2):1773-1786.
[23]	ZHAO J Y,TANG Q Q,LUO Y T,et al.Predictive value of a serum tumor biomarkers scoring system for clinical stageⅡ/Ⅲrectal cancer with neoadjuvant chemoradiotherapy[J].World JGastrointest Oncol,2022,14(10):2014-2024.
[24]	SOKOŁOWSKA J,URBAN'SKA K.Immunohistochemical assessment of metalloproteinases MMP2 and MMP9 expression in canine various subtypes of lymphomas in relation with proliferative and apoptotic markers[J].Pol J Vet Sci,2019,22(2):203-211.
[25]	RAPOSO T P,BEIRÃO B C,PIRES I,et al.Immunohistochemical expression of CCR2,CSF1R and MMP9 in canine inflammatory mammary carcinomas[J].Anticancer Res,2016,36(4):1805-1813.
[26]	GEBHARD C,FUCHS-BAUMGARTINGER A,RAZZAZI-FAZELI E,et al.Distribution and activity levels of matrix metalloproteinase 2 and 9 in canine and feline osteosarcoma[J].Can J Vet Res,2016,80(1):66-73.
[27]	VAN TUBERGEN E A,BANERJEE R,LIU M,et al.Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9,MMP2,and IL-6[J].Clin Cancer Res,2013,19 (5):1169-1179.
[28]	SUN Y,CHEN Y,LI S,et al.Nano Velcro-captured CTC number concomitant with enhanced serum levels of MMP7 and MMP9enables accurate prediction of metastasis and poor prognosis in patients with lung adenocarcinoma[J].Int J Nanomed,2017,12:6399-6412.
[29]	WU X Z,CHEN D,XIE G R.Extracellular matrix remodeling in hepatocellular carcinoma:effects of soil on seed[J].Med Hypotheses,2005,66(6):1115-1120.
[30]	KHALIL R A.Biochemical and biological attributes of matrix metalloproteinases[J].Prog Mol Biol Transl Sci,2017,147:1-73.
[31]	HANAHAN D,WEINBERG R A.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[32]	TURAJLIC S,SWANTON C.Metastasis as an evolutionary process[J].Science,2016,352(6282):169-175.
[33]	JIANG K,CHEN H,FANG Y,et al.Exosomal ANGPTL1attenuates colorectal cancer liver metastasis by regulating Kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness[J].J Exp Clin Cancer Res,2021,40(1):21.
[34]	MURPHY G.Riding the metalloproteinase roller coaster[J].J Biol Chem,2017,292(19):7708-7718.
[35]	SUN Z,ZHANG N.Clinical evaluation of CEA,CA19-9,CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy[J].World J Surg Oncol,2014,12:397.
[36]	VALENCAKOVA-AGYAGOSOVA A,FRISCHOVA Z,SEVCIKOVA Z,et al.Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland:preliminary report[J].Vet Comp Oncol,2014,12 (3):205-214.
[37]	MALOV S I,MALOV I V,KUVSHINOV A G,et al.Search for effective serum tumor markers for early diagnosis of hepatocellular carcinoma associated with hepatitis C[J].Sovrem Tekhnologii Med,2021,13(1):27-33.
[38]	HEISHIMA K,ICHIKAWA Y,YOSHIDA K,et al.Circulating microRNA-214 and-126 as potential biomarkers for canine neoplastic disease[J].Scientific Rep,2017,7(1):2301.
[39]	FATHIPOUR V,KHAKI Z,NASSIRI S M,et al.Prognostic value of zymographic gelatinase activity of MMP-2 and MMP-9 in tumor recurrence of canine intrascrotal hemangiomas[J].J Comp Pathol,2020,29(1):25-31.